Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment

Phase II study

Antonio Llombart-Cussac, Maria Theodoulou, Kendrith Rowland, Romnee Clark, Takashi Nakamura, Eva Carrasco, Giorgio Cruciani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer. Patients and Methods: Patients with advanced-stage or metastatic breast cancer, Eastern Cooperative Oncology Group performance status 0-2, and progressive or relapsed disease after treatment with regimens containing anthracyclines and taxanes were eligible. Pemetrexed 500 mg/m2 was administered as a 10-minute intravenous infusion on day 1 every 21 days. Results: Seventy-nine women were enrolled. After protocol amendment, 43 patients received folic acid and vitamin B12 supplementation to control pemetrexed-related toxicity. A median of 4 cycles (range, 1-23 cycles) was administered. Overall response rate was 9% (95% confidence interval, 3.7%-17.6%), median duration of response was 5.5 months, median progression-free survival was 3.1 months, and median survival was 10.5 months. Major grade 3/4 toxicities were lymphopenia (53.3%), neutropenia (36.4%), leukopenia (26.9%), and anemia (7.7%). In general, the toxicities were less frequent in patients who received vitamin supplementation than in those who did not receive vitamin supplementation. Conclusion: The response to pemetrexed salvage treatment was low in this study of heavily pretreated patients with breast cancer. Pemetrexed was generally well tolerated in patients with previously treated breast cancer. Vitamin supplementation appeared to ameliorate toxicity.

Original languageEnglish (US)
Pages (from-to)380-385
Number of pages6
JournalClinical Breast Cancer
Volume7
Issue number5
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Pemetrexed
Anthracyclines
Breast Neoplasms
Vitamins
Therapeutics
Taxoids
Salvage Therapy
Lymphopenia
Leukopenia
Vitamin B 12
taxane
Neutropenia
Folic Acid
Intravenous Infusions
Disease-Free Survival
Anemia
Confidence Intervals
Safety

Keywords

  • Multitargeted antifolate
  • Progressive disease
  • Salvage treatment
  • Vitamin supplementation

ASJC Scopus subject areas

  • Cancer Research

Cite this

Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment : Phase II study. / Llombart-Cussac, Antonio; Theodoulou, Maria; Rowland, Kendrith; Clark, Romnee; Nakamura, Takashi; Carrasco, Eva; Cruciani, Giorgio.

In: Clinical Breast Cancer, Vol. 7, No. 5, 2006, p. 380-385.

Research output: Contribution to journalArticle

Llombart-Cussac, Antonio ; Theodoulou, Maria ; Rowland, Kendrith ; Clark, Romnee ; Nakamura, Takashi ; Carrasco, Eva ; Cruciani, Giorgio. / Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment : Phase II study. In: Clinical Breast Cancer. 2006 ; Vol. 7, No. 5. pp. 380-385.
@article{54ee5d2594c24870879f48f8a125aa69,
title = "Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: Phase II study",
abstract = "Purpose: The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer. Patients and Methods: Patients with advanced-stage or metastatic breast cancer, Eastern Cooperative Oncology Group performance status 0-2, and progressive or relapsed disease after treatment with regimens containing anthracyclines and taxanes were eligible. Pemetrexed 500 mg/m2 was administered as a 10-minute intravenous infusion on day 1 every 21 days. Results: Seventy-nine women were enrolled. After protocol amendment, 43 patients received folic acid and vitamin B12 supplementation to control pemetrexed-related toxicity. A median of 4 cycles (range, 1-23 cycles) was administered. Overall response rate was 9{\%} (95{\%} confidence interval, 3.7{\%}-17.6{\%}), median duration of response was 5.5 months, median progression-free survival was 3.1 months, and median survival was 10.5 months. Major grade 3/4 toxicities were lymphopenia (53.3{\%}), neutropenia (36.4{\%}), leukopenia (26.9{\%}), and anemia (7.7{\%}). In general, the toxicities were less frequent in patients who received vitamin supplementation than in those who did not receive vitamin supplementation. Conclusion: The response to pemetrexed salvage treatment was low in this study of heavily pretreated patients with breast cancer. Pemetrexed was generally well tolerated in patients with previously treated breast cancer. Vitamin supplementation appeared to ameliorate toxicity.",
keywords = "Multitargeted antifolate, Progressive disease, Salvage treatment, Vitamin supplementation",
author = "Antonio Llombart-Cussac and Maria Theodoulou and Kendrith Rowland and Romnee Clark and Takashi Nakamura and Eva Carrasco and Giorgio Cruciani",
year = "2006",
doi = "10.3816/CBC.2006.n.054",
language = "English (US)",
volume = "7",
pages = "380--385",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment

T2 - Phase II study

AU - Llombart-Cussac, Antonio

AU - Theodoulou, Maria

AU - Rowland, Kendrith

AU - Clark, Romnee

AU - Nakamura, Takashi

AU - Carrasco, Eva

AU - Cruciani, Giorgio

PY - 2006

Y1 - 2006

N2 - Purpose: The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer. Patients and Methods: Patients with advanced-stage or metastatic breast cancer, Eastern Cooperative Oncology Group performance status 0-2, and progressive or relapsed disease after treatment with regimens containing anthracyclines and taxanes were eligible. Pemetrexed 500 mg/m2 was administered as a 10-minute intravenous infusion on day 1 every 21 days. Results: Seventy-nine women were enrolled. After protocol amendment, 43 patients received folic acid and vitamin B12 supplementation to control pemetrexed-related toxicity. A median of 4 cycles (range, 1-23 cycles) was administered. Overall response rate was 9% (95% confidence interval, 3.7%-17.6%), median duration of response was 5.5 months, median progression-free survival was 3.1 months, and median survival was 10.5 months. Major grade 3/4 toxicities were lymphopenia (53.3%), neutropenia (36.4%), leukopenia (26.9%), and anemia (7.7%). In general, the toxicities were less frequent in patients who received vitamin supplementation than in those who did not receive vitamin supplementation. Conclusion: The response to pemetrexed salvage treatment was low in this study of heavily pretreated patients with breast cancer. Pemetrexed was generally well tolerated in patients with previously treated breast cancer. Vitamin supplementation appeared to ameliorate toxicity.

AB - Purpose: The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer. Patients and Methods: Patients with advanced-stage or metastatic breast cancer, Eastern Cooperative Oncology Group performance status 0-2, and progressive or relapsed disease after treatment with regimens containing anthracyclines and taxanes were eligible. Pemetrexed 500 mg/m2 was administered as a 10-minute intravenous infusion on day 1 every 21 days. Results: Seventy-nine women were enrolled. After protocol amendment, 43 patients received folic acid and vitamin B12 supplementation to control pemetrexed-related toxicity. A median of 4 cycles (range, 1-23 cycles) was administered. Overall response rate was 9% (95% confidence interval, 3.7%-17.6%), median duration of response was 5.5 months, median progression-free survival was 3.1 months, and median survival was 10.5 months. Major grade 3/4 toxicities were lymphopenia (53.3%), neutropenia (36.4%), leukopenia (26.9%), and anemia (7.7%). In general, the toxicities were less frequent in patients who received vitamin supplementation than in those who did not receive vitamin supplementation. Conclusion: The response to pemetrexed salvage treatment was low in this study of heavily pretreated patients with breast cancer. Pemetrexed was generally well tolerated in patients with previously treated breast cancer. Vitamin supplementation appeared to ameliorate toxicity.

KW - Multitargeted antifolate

KW - Progressive disease

KW - Salvage treatment

KW - Vitamin supplementation

UR - http://www.scopus.com/inward/record.url?scp=33846552380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846552380&partnerID=8YFLogxK

U2 - 10.3816/CBC.2006.n.054

DO - 10.3816/CBC.2006.n.054

M3 - Article

VL - 7

SP - 380

EP - 385

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -